Abiraterone acetate

Abiraterone acetate 117 is an androgen biosynthesis inhibitor, which was developed by the Institute of Cancer Research in the UK and further developed by Janssen for the oral treatment of patients with metastatic castration-resistant prostate cancer [75]. Its synthesis is relatively easy through a Suzuki coupling between the 17-enol triflate derived from the 3-acetate of dehydro-epiandrosterone (115) and 3-pyridyl-diethylborane (116) (Scheme 27) [76]. The reaction is catalysed by PdCl2(PPh3)2 and proceeds in good yield (84%). A similar Suzuki-based route in which the ketone starting material was converted into an alkenyliodide has also been published [77]. [Pg.20]

Scheme 27 The Suzuki reaction in the synthesis of Abiraterone acetate...

NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Deamaley D, Kheoh T, Molina A, de Bono JS (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27 3742 3748... [Pg.257]

LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28 1489-1495... [Pg.257]

Shah S, Ryan C (2010) Abiraterone acetate for castration resistant prostate cancer. Exp Opin Invest Drugs 19 563 570... [Pg.257]

Yang LP (2011) Abiraterone acetate in metastatic castration-resistant prostate cancer. Drugs 71 2067-2077... [Pg.257]

Rehman Y, Rosenberg JE (2012) Abiraterone acetate oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drag Des Devel Ther 6 13-18... [Pg.257]

CYP17 inhibitor abiraterone acetate. J Clin Oncol... [Pg.763]

Big Chemical Encyclopedia